Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million

Core Viewpoint - Johnson & Johnson has completed the acquisition of V-Wave Ltd for $600 million, which will enhance its capabilities in cardiovascular disease treatment solutions [1] Group 1: Acquisition Details - The acquisition of V-Wave Ltd is classified as an asset acquisition [1] - Johnson & Johnson will incur approximately $600 million in in-process research and development expenses in Q4 2024 due to this transaction [1] Group 2: Financial Impact - The acquisition is projected to dilute Johnson & Johnson's adjusted earnings per share by approximately $0.24 in 2024 [1] - The expected dilution in adjusted earnings per share is estimated to be around $0.06 in 2025 [1] Group 3: Operational Integration - V-Wave will operate under Johnson & Johnson's medtech division following the acquisition [1]